EXO1 is a promising target to treat BRCA1-deficient breast cancer. Sebastian Pomplun and Sylvie Noordermeer have just received €1.18 Mio by…
Conversation activity · last 22 hours presspostscomments the crowd ↓
Every item, in order 3
Clustered from 3 items across 1 source. Not yet parsed — the coverage below is the raw record.
Social posts 1
The conversation unedited, verbatim
3 collected here from 1 site · 2 voices below over time ↑
- Yesterday
-
How can a specific weakness of the tumor be targeted to treat cancer? For the case of BRCA1-deficient breast cancer, the groups of Sebastian Pomplun and Sylvie Noordermeer are now setting out to address this question by targeting EXO1. Read the full story: https://www. staff.universiteitleiden.nl/ne…
-
EXO1 is a promising target to treat BRCA1-deficient breast cancer. Sebastian Pomplun and Sylvie Noordermeer have just received €1.18 Mio by the KWF to tackle this promising, but challenging target. Here, you can read an insightful explanation of their project: https://www. staff.universiteitleiden.nl/ne…